Evidence-based guideline for prevention, recognition, and management of chemotherapy extravasation injuries, including agent classification, antidote protocols, and follow-up care.
A comprehensive, evidence-based clinical guideline for the prevention, early recognition, and management of chemotherapy extravasation injuries. This document synthesizes recommendations from multiple international professional societies and expert panels in oncology, oncology nursing, infusion therapy, and supportive care to provide a single, authoritative reference for clinicians involved in the administration of antineoplastic agents.
Chemotherapy extravasation — the inadvertent leakage or infiltration of a cytotoxic agent from the intended vascular pathway into surrounding tissues — remains a significant iatrogenic complication in oncology practice. Reported incidence rates for peripheral intravenous extravasation range from 0.1% to 6.0% of all chemotherapy administrations, with central venous access device extravasation occurring at rates of 0.3% to 4.7%.1 The consequences of extravasation vary from mild local discomfort to severe tissue necrosis requiring surgical debridement, skin grafting, or in rare cases, amputation. Prevention through meticulous technique, appropriate patient selection, vigilant monitoring, and standardized institutional protocols is the primary objective. When extravasation does occur, the outcome depends critically on rapid recognition and the immediate initiation of agent-specific management, including administration of appropriate antidotes within defined time windows.2
This guideline is organized into three parts covering the complete spectrum of chemotherapy extravasation prevention and management:
Contents:
| Part | Title | Coverage |
|---|---|---|
| Part 1 | Agent Classification, Risk Factors, and Prevention | Complete classification of antineoplastic agents as vesicants, irritants, and non-vesicants; patient-related, procedure-related, and drug-related risk factors; vein selection, device selection, administration technique, and monitoring strategies |
| Part 2 | Recognition and Immediate Management | Signs and symptoms of extravasation (early and late); differential diagnosis; immediate management algorithm; aspiration technique; specific antidote protocols with complete dosing for dexrazoxane, hyaluronidase, sodium thiosulfate, and DMSO; thermal management by agent class |
| Part 3 | Follow-Up Care, Documentation, Legal Considerations, and Staff Education | Surgical consultation criteria; wound assessment and grading; patient follow-up protocols; peripheral vs. central line extravasation considerations; documentation requirements; incident reporting; legal and medicolegal considerations; staff education and competency assessment; institutional protocol development |
Scope and Applicability: This guideline applies to all healthcare professionals involved in the prescribing, preparation, administration, and monitoring of intravenous antineoplastic agents in adult and pediatric patients across all care settings, including inpatient oncology units, outpatient infusion centers, and home infusion programs.
Limitations: No guideline can anticipate all clinical situations. This document is not intended to replace individual clinical judgment by qualified professionals. Local institutional protocols, formulary availability, and patient-specific factors must always be considered in clinical decision-making.
Pérez Fidalgo JA, García Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F. “Management of chemotherapy extravasation: ESMO–EONS Clinical Practice Guidelines.” Annals of Oncology, 23(suppl 7): vii167–vii173, 2012. European Society for Medical Oncology (ESMO) and European Oncology Nursing Society (EONS). DOI: 10.1093/annonc/mds294 ↩︎
Schulmeister L. “Extravasation management: clinical update.” Seminars in Oncology Nursing, 27(1): 82–90, 2011. DOI: 10.1016/j.soncn.2010.11.010 ↩︎
Surgical consultation criteria, wound grading, patient follow-up protocols, peripheral vs. central line extravasation management, documentation requirements, incident reporting, legal considerations, staff competency assessment, and institutional protocol development.
Signs and symptoms of extravasation (early and late), differential diagnosis, step-by-step immediate management algorithm, specific antidote protocols with complete dosing for dexrazoxane, hyaluronidase, sodium thiosulfate, and DMSO, and thermal management by agent class.
Complete classification of antineoplastic agents by tissue damage potential (vesicants, irritants, non-vesicants), comprehensive risk factor analysis, and evidence-based prevention strategies including vein selection, device selection, and monitoring protocols.